Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson's disease?

Journal of Neural Transmission

Volumn 118, Issue 4, 2011, Pages 539-543

  Hassin Baer, Sharon ^a,b   Cohen, Oren S ^a,b   Vakil, Eli ^c   Molshazki, Noa ^a,b   Sela, Ben Ami ^a,b   Nitsan, Zeev ^a   Chapman, Joab ^a,b   Tanne, David ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

C reactive protein; Inflammation; Neuropsychiatric complications; Parkinson's disease; Risk factor

Indexed keywords

C REACTIVE PROTEIN; LEVODOPA;

ADOLESCENT; ADULT; ARTICLE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FRONTAL LOBE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; COGNITION DISORDERS; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; MOOD DISORDERS; MOVEMENT DISORDERS; PARKINSON DISEASE; PROSPECTIVE STUDIES;

EID: 79956203293     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0535-z     Document Type: Article

References (27)

1. Berk M, Wadee AA, Kuschke RH, O'Neill-Kerr A (1997) Acute phase proteins in major depression. J Psychosom Res 43:529-534 (Pubitemid 27487544)
2. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A (2008) Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 167(1):90-95
3. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15:991-998 (Pubitemid 35463634)
4. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F (1993) Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52:1-6 (Pubitemid 23026600)
5. Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55:1621-1626
6. Duong T, Nikolaeva M, Acton PJ (1997) C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease. Brain Res 749:152-156 (Pubitemid 27096469)
7. Duong T, Acton PJ, Johnson RA (1998) The in vitro neuronal toxicity of pentraxins associated with Alzheimer's disease brain lesions. Brain Res 813:303-312 (Pubitemid 29009646)
8. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
9. Friedberg G, Zoldan J, Weizman A, Melamed E (1998) Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 21:280-284 (Pubitemid 28491427)
10. Greenamyre JT, MacKenzie G, Peng TI, Stephans SE (1999) Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp 66:85-97 (Pubitemid 129639025)
11. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8:382-397
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184
13. Iwamoto N, Nishiyama E, Ohwada J, Arai H (1994) Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett 177:23-26 (Pubitemid 24269420)
14. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F (2005) Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 4:371-380
15. Leentjens AF, Verhey FR, Luijckx GJ, Troost J (2000) The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord 15:1221-1224
16. Lezak M (1995) Neuropsychological assessment, 3rd edn. Oxford University Press, New York
17. Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D Jr, Hagg T, Hardy J, Jenner P, Myers RH, Price D, Hallett M, Langston WJ, Lang AE, Halliday G, Rocca W, Duyckaerts C, Dickson DW, Ben-Shlomo Y, Goetz CG, Melamed E (2007) The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol 66(5):329-336 (Pubitemid 46701314)
18. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285-1291
19. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA (2002) Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 90:1279-1283 (Pubitemid 35449470)
20. Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 11:999-1016 (Pubitemid 40331301)
21. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L (2004) C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109:647-655 (Pubitemid 38198873)
22. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511
23. Silverman JM, Beeri MS, Schmeidler J, Rosendorff C, Angelo G, Mavris RS, Grossman HT, Elder GA, Carrion-Baralt J, West R (2009) C-reactive protein and memory function suggest antagonistic pleiotropy in very old nondemented subjects. Age Ageing 38(2):237-241
24. Song IU, Kim JS, Chung SW, Lee KS (2009) Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson's disease? A comparison of Parkinson's disease patients, disease controls and healthy individuals. Eur Neurol 62(2):99-104
25. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100:5473-5478 (Pubitemid 36542729)
26. Vakil E, Blachstein H (1997) Rey AVLT: developmental norms for adults and the sensitivity of different memory measures to age. Clin Neuropsychol 11:345-355
27. Wechsler D (1997) Wechsler Memory Scale, 3rd edn. Psychological Corporation, San Antonio